Unlearn and Merck collaborate on medical twins trials

Unlearn and Merck KGaA have announced a partnership to accelerate drug trials using medical digital twins of patients. Unlearn uses recent developments from deep learning to create digital twins of patients in clinical trials. The new technique allows drug researchers to reduce the size of control arms by 30% or more and generate reliable clinical evidence in less time. Merck plans to focus on late-stage clinical trials for immunology drugs initially.

Read the source article at VentureBeat
2022-02-16 22:22:56